Franklin Biotechnology Discovery R6 FRBRX

Medalist Rating as of | See Franklin Templeton Investment Hub
  • NAV / 1-Day Return 156.03  /  −1.29 %
  • Total Assets 909.8 Mil
  • Adj. Expense Ratio
    0.690%
  • Expense Ratio 0.690%
  • Distribution Fee Level Low
  • Share Class Type Retirement, Large
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 1.0 Mil
  • Status Open
  • TTM Yield 0.00
  • Turnover 36%

USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:10 PM GMT+0

Morningstar’s Analysis FRBRX

Will FRBRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Experienced team but not yet a standout.

Director Katie Rushkewicz Reichart

Katie Rushkewicz Reichart

Director

Summary

Franklin Biotechnology Discovery has an experienced team at the helm, but it needs to distinguish itself.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FRBRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

8.16 77.4 Mil
Healthcare

Regeneron Pharmaceuticals Inc

7.78 73.7 Mil
Healthcare

Vertex Pharmaceuticals Inc

6.00 56.9 Mil
Healthcare

Insmed Inc

3.92 37.1 Mil
Healthcare

Gilead Sciences Inc

3.37 31.9 Mil
Healthcare

AstraZeneca PLC ADR

3.11 29.5 Mil
Healthcare

Biogen Inc

2.79 26.5 Mil
Healthcare

Intra-Cellular Therapies Inc

2.75 26.0 Mil
Healthcare

Merus NV

2.69 25.5 Mil
Healthcare

Jazz Pharmaceuticals PLC

2.65 25.1 Mil
Healthcare

Sponsor Center